Adjuvatis

Executive Summary

Adjuvatis is a French biotechnology company founded in 2016, headquartered in Lyon, specializing in the development of i-Particles® technology, a novel vaccine and immunology platform based on a 'safe-by-design' principle. The platform aims to eliminate harmful by-products and enhance patient safety by leveraging engineered particles that stimulate immune responses without toxicity. Although the company is in an early stage with limited public information on funding or pipeline, its unique approach positions it as a potential disruptor in vaccine adjuvant technology. The lack of disclosed financials or clinical data suggests preclinical or early development phase, but the strong safety focus aligns with industry trends toward safer immunotherapies. As a private entity, Adjuvatis may seek partnerships or funding to advance its platform into clinical trials, targeting infectious diseases or cancer immunotherapy. The company's innovation could address key limitations of conventional adjuvants, offering better tolerability and efficacy.

Upcoming Catalysts (preview)

• Q2 2027Series A Funding Round to Advance i-Particles® Platform40% success
• Q4 2026Preclinical Proof-of-Concept Data Publication60% success
• Q3 2027Strategic Licensing or Collaboration with Pharmaceutical Partner30% success